Comment on: Carboplatin Hypersensitivity Reactions in Pediatric Low-Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy.

@article{Gen2016CommentOC,
  title={Comment on: Carboplatin Hypersensitivity Reactions in Pediatric Low-Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy.},
  author={Dildar Bahar Genç and Su G{\"u}ls{\"u}n Berrak and Cengiz Canpolat},
  journal={Pediatric blood & cancer},
  year={2016},
  volume={63 1},
  pages={174}
}
To the Editor: We read with great interest the article recently published by Dodgshun et al.[1] The authors describe 16 patients with carboplatin-related hypersensitivity reactions (CRHR) among 34 patients treated for pediatric low-grade glioma (LGG). Ten patients were rechallenged with carboplatin with a carboplatin continuation rate of 20%. The reason for carboplatin termination in four patients with grade II reactions was not documented. The authors point to the inefficacy of carboplatin… CONTINUE READING